Behnam Mohammadi

Dr. Behnam Mohammadi

Institute of Neuropathology at UKE, Hamburg, Hamburg, Germany
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2020 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
SBSantra Brenna
Santra Brenna
HAHermann Altmeppen
Hermann Altmeppen
BMBehnam Mohammadi
Behnam Mohammadi
BRBjörn Rissiek
Björn Rissiek
FSFlorence Schlink
Florence Schlink
TMTim Magnus
Tim Magnus
Extracellular vesicles (EVs) are important means of intercellular communication and a potent tool for regenerative therapy. In ischaemic stroke, transient blockage of a brain artery leads to a lack of glucose and oxygen in the affected brain tissue, provoking neuronal death by necrosis in the core of the ischaemic region. The fate of neurons in the surrounding penumbra region depends on the stimuli, including EVs, received during the following hours. A detailed characterization of such stimuli is crucial not only for understanding stroke pathophysiology but also for new therapeutic interventions. In the present study, we characterize the EVs in mouse brain under physiological conditions and 24 h after induction of transient ischaemia in mice. We show that, in steady‐state conditions, microglia are the main source of small EVs (sEVs), whereas after ischaemia the main sEV population originates from astrocytes. Brain sEVs presented high amounts of the prion protein (PrP), which were further increased after stroke. Moreover, EVs were enriched in a proteolytically truncated PrP fragment (PrP‐C1). Because of similarities between PrP‐C1 and certain viral surface proteins, we studied the cellular uptake of brain‐derived sEVs from mice lacking (PrP‐KO) or expressing PrP (WT). We show that PrP‐KO‐sEVs are taken up significantly faster and more efficiently than WT‐EVs by primary neurons. Furthermore, microglia and astrocytes engulf PrP‐KO‐sEVs more readily than WT‐sEVs. Our results provide novel information on the relative contribution of brain cell types to the sEV pool in murine brain and indicate that increased release of sEVs by astrocytes together with elevated levels of PrP in sEVs may play a role in intercellular communication at early stages after stroke. In addition, amounts of PrP (and probably PrP‐C1) in brain sEVs seem to contribute to regulating their cellular uptake.

1 November 2017 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
LLLuise Linsenmeier
Luise Linsenmeier
HAHermann Altmeppen
Hermann Altmeppen
SWSebastian Wetzel
Sebastian Wetzel
BMBehnam Mohammadi
Behnam Mohammadi
PSPaul Saftig
Paul Saftig
MGMarkus Glatzel
Markus Glatzel

15 July 2023 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
MWMarcel S. Woo
Marcel S. Woo
MSMohsin Shafiq
Mohsin Shafiq
AFAntonia Fitzek
Antonia Fitzek
MDMatthias Dottermusch
Matthias Dottermusch
HAHermann Altmeppen
Hermann Altmeppen
MGMarkus Glatzel
Markus Glatzel
Dysautonomia has substantially impacted acute COVID-19 severity as well as symptom burden after recovery from COVID-19 (long COVID), yet the underlying causes remain unknown. Here, we hypothesized that vagus nerves are affected in COVID-19 which might contribute to autonomic dysfunction. We performed a histopathological characterization of postmortem vagus nerves from COVID-19 patients and controls, and detected SARS-CoV-2 RNA together with inflammatory cell infiltration composed primarily of monocytes. Furthermore, we performed RNA sequencing which revealed a strong inflammatory response of neurons, endothelial cells, and Schwann cells which correlated with SARS-CoV-2 RNA load. Lastly, we screened a clinical cohort of 323 patients to detect a clinical phenotype of vagus nerve affection and found a decreased respiratory rate in non-survivors of critical COVID-19. Our data suggest that SARS-CoV-2 induces vagus nerve inflammation followed by autonomic dysfunction which contributes to critical disease courses and might contribute to dysautonomia observed in long COVID.

30 March 2015 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
DMDurga Praveen Meka
Durga Praveen Meka
AMAnne Kathrin Müller-Rischart
Anne Kathrin Müller-Rischart
PNPrakash Nidadavolu
Prakash Nidadavolu
BMBehnam Mohammadi
Behnam Mohammadi
EMElisa Motori
Elisa Motori
Edgar Richard KramerEdgar Richard Kramer
Edgar Richard Kramer
Parkin and the glial cell line–derived neurotrophic factor (GDNF) receptor RET have both been independently linked to the dopaminergic neuron degeneration that underlies Parkinson’s disease (PD). In the present study, we demonstrate that there is genetic crosstalk between parkin and the receptor tyrosine kinase RET in two different mouse models of PD. Mice lacking both parkin and RET exhibited accelerated dopaminergic cell and axonal loss compared with parkin-deficient animals, which showed none, and RET-deficient mice, in which we found moderate degeneration. Transgenic expression of parkin protected the dopaminergic systems of aged RET-deficient mice. Downregulation of either parkin or RET in neuronal cells impaired mitochondrial function and morphology. Parkin expression restored mitochondrial function in GDNF/RET-deficient cells, while GDNF stimulation rescued mitochondrial defects in parkin-deficient cells. In both cases, improved mitochondrial function was the result of activation of the prosurvival NF-κB pathway, which was mediated by RET through the phosphoinositide-3-kinase (PI3K) pathway. Taken together, these observations indicate that parkin and the RET signaling cascade converge to control mitochondrial integrity and thereby properly maintain substantia nigra pars compacta dopaminergic neurons and their innervation in the striatum. The demonstration of crosstalk between parkin and RET highlights the interplay in the protein network that is altered in PD and suggests potential therapeutic targets and strategies to treat PD.

6 April 2018 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
LLLuise Linsenmeier
Luise Linsenmeier
BMBehnam Mohammadi
Behnam Mohammadi
SWSebastian Wetzel
Sebastian Wetzel
Berta PuigBerta Puig
Berta Puig
WJWalker Jackson
Walker Jackson
HAHermann Altmeppen
Hermann Altmeppen
Proteolytic processing of the prion protein (PrPC) by endogenous proteases generates bioactive membrane-bound and soluble fragments which may help to explain the pleiotropic roles of this protein in the nervous system and in brain diseases. Shedding of almost full-length PrPC into the extracellular space by the metalloprotease ADAM10 is of peculiar relevance since soluble PrP stimulates axonal outgrowth and is protective in neurodegenerative conditions such as Alzheimer’s and prion disease. However, molecular determinates and mechanisms regulating the shedding of PrP are entirely unknown. We produced an antibody recognizing the neo-epitope of shed PrP generated by ADAM10 in biological samples and used it to study structural and mechanistic aspects affecting the shedding. For this, we investigated genetically modified cellular and murine models by biochemical and morphological approaches. We show that the novel antibody specifically detects shed PrP in cell culture supernatants and murine brain. We demonstrate that ADAM10 is the exclusive sheddase of PrPC in the nervous system and reveal that the glycosylation state and type of membrane-anchorage of PrPC severely affect its shedding. Furthermore, we provide evidence that PrP shedding can be modulated by pharmacological inhibition and stimulation and present data suggesting that shedding is a relevant part of a compensatory network ensuring PrPC homeostasis of the cell. With the new antibody, our study introduces a new tool to reliably investigate PrP-shedding. In addition, this study provides novel and important insight into the regulation of this cleavage event, which is likely to be relevant for diagnostic and therapeutic approaches even beyond neurodegeneration.

26 November 2021 in Science Advances
Verified
Journal Article
Open access
LLLuise Linsenmeier
Luise Linsenmeier
BMBehnam Mohammadi
Behnam Mohammadi
MSMohsin Shafiq
Mohsin Shafiq
KFKarl Frontzek
Karl Frontzek
JBJulia Bär
Julia Bär
MGMarkus Glatzel
Markus Glatzel
Ligand-stimulated enzymatic release or cellular degradation of PrP may interfere with neurodegeneration-associated toxicity.